Left ventricular assist device for end-stage heart failure: results of the first LVAD destination program in the Netherlands

Purpose Mechanical circulatory support with a continuous-flow left ventricular assist device (LVAD) may be a valuable treatment in end-stage heart failure patients for an extended period of time. The purpose of this study was to evaluate the safety and efficacy of implantation of a continuous-flow L...

Full description

Saved in:
Bibliographic Details
Published in:Netherlands heart journal 2015-02, Vol.23 (2), p.102-108
Main Authors: Haeck, M. L. A., Beeres, S. L. M. A., Höke, U., Palmen, M., Couperus, L. E., Delgado, V., Logeman, E. A., Maas, J. J., Klautz, R. J. M., Schalij, M. J., Verwey, H. F.
Format: Article
Language:English
Subjects:
Cardiology
Contraindications
Ejection fraction
Extracorporeal membrane oxygenation
Heart failure
Heart transplants
Hospitals
Intensive care
Ischemia
Laboratories
Maximum oxygen consumption
Medical Education
Medicine
Medicine & Public Health
Original Article E-learning
Original E-learning
Ostomy
Patients
Pulmonary arteries
Thoracic surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Mechanical circulatory support with a continuous-flow left ventricular assist device (LVAD) may be a valuable treatment in end-stage heart failure patients for an extended period of time. The purpose of this study was to evaluate the safety and efficacy of implantation of a continuous-flow LVAD in end-stage heart failure patients within the first destination program in the Netherlands. Methods A third-generation LVAD was implanted in 16 heart failure patients (age 61 ± 8; 81 % male; left ventricular ejection fraction 20 ± 6 %) as destination therapy. All patients were ineligible for heart transplant. At baseline, 3 and 6 months, New York Heart Association (NYHA) functional class, quality-of-life and exercise capacity were assessed. Clinical adverse events were registered. Results Survival at 30 days and 6 months was 88 and 75 %, respectively. In the postoperative phase, 6 (38 %) patients required continuous veno-venous haemofiltration for renal failure and 2 (13 %) patients required extracorporeal membrane oxygenation because of severe right ventricular failure. During follow-up, NYHA functional class and quality-of-life improved from 3.7 ± 0.1 to 2.3 ± 0.1 and 57 ± 5 to 23 ± 3 at 6 months ( P  
ISSN:1568-5888
1876-6250
DOI:10.1007/s12471-014-0602-4